| Flat View | Wednesday, April 29, 2026 |
|
| Tuesday, September 01, 2015 |
 |
9th American Biotechnology Congress Aug 31 - Sep 2, 2015 Florida, USA ( 8:00 am )
9th American Biotechnology Congress Aug 31 - Sep 2, 2015 Florida, USA
Omics Group invites the contributors across the globe to participate in the premier 9th American biotechnology congress (Bio America-2015), to discuss the theme: "Biotechnology-emerging trends for a Sustainable Future". The conference will be held at the Florida, USA during August 31-september 02, 2015.
Conference Highlights
Biotechnology in Health Care
Stem Cell Research and Therapy
Analytical and Bio analytical Methodology
Biotechnology in Agriculture
Food and Bioprocess Technology
Animal biotechnology and Cell Culture
Environmental Biotechnology and Bioenergy
Nanobiotechnology and Application
Tissue Engineering and Regenerative Medicine
Genetic Engineering and rDNA Technology
Biochemistry, Cell , Molecular and Microbiology
Bioinformatics, Biosensors and Omics Studies
Other allied areas of Biotechnology
Url: http://www.biotechnologycongress.com/
| |
| Wednesday, September 02, 2015 |
 |
9th American Biotechnology Congress Aug 31 - Sep 2, 2015 Florida, USA ( 8:00 am )
9th American Biotechnology Congress Aug 31 - Sep 2, 2015 Florida, USA
Omics Group invites the contributors across the globe to participate in the premier 9th American biotechnology congress (Bio America-2015), to discuss the theme: "Biotechnology-emerging trends for a Sustainable Future". The conference will be held at the Florida, USA during August 31-september 02, 2015.
Conference Highlights
Biotechnology in Health Care
Stem Cell Research and Therapy
Analytical and Bio analytical Methodology
Biotechnology in Agriculture
Food and Bioprocess Technology
Animal biotechnology and Cell Culture
Environmental Biotechnology and Bioenergy
Nanobiotechnology and Application
Tissue Engineering and Regenerative Medicine
Genetic Engineering and rDNA Technology
Biochemistry, Cell , Molecular and Microbiology
Bioinformatics, Biosensors and Omics Studies
Other allied areas of Biotechnology
Url: http://www.biotechnologycongress.com/
| |
| Friday, September 04, 2015 |
 |
Professional Certification In Translational Medicine (PCTM) September 4, 2015 Vienna, Austria ( 8:00 am )
Professional Certification in Translational Medicine (PCTM) September 4, 2015 Vienna, AustriaEvent location: Falkensteiner Hotel Wien Margareten Vienna, Austria http://www.falkensteiner.com/en/hotel/margareten Professional Certification in Translational Medicine (PCTM) program is designed by the Academy of Translational Medicine Professionals (ATMP) to set the standards for excellence in field of translational medicine and to promote and maintain high quality in clinical research Program Accreditation Professional Certification in Translational Medicine (PCTM) program is accredited by the European Society for Translational Medicine (EUSTM). After certification approval, successful individuals may use the title (PCTM). Certification is valid for two years from date of certification approval. Certification renewal application can be made after two years. Certification Benefits - Increased Job Opportunities Professional certification will increase your job opportunities and accelerate your promotions by highlighting you from other colleagues and pool of other candidates. - Stay-Up-To-Date Professional certification will ensure translational medicine knowledge and skills are up to date. - Show Your Competency Professional certification will show your competency to conduct and manage translational research studies. - Demonstrate Your Commitment Professional certification demonstrates your commitment to the advancement of clinical research. PCTM Preparatory Course To prepare for the PCTM qualifying examination, preparatory course would be held on 4th September, 2015 in Vienna, Austria. PCTM Qualifying Examination In order to receive PCTM title, applicants must pass the qualifying exam (MCQs type) held on 4th September, 2015 (one hour duration). Registration Fees - PCTM Preparatory Course: 400 € - PCTM Qualifying Examination: 150 €
Contact Info : Academy of Translational Medicine Professionals (ATMP)
European Society for Translational Medicine (EUSTM)
Schönbrunner Straße 293/10/12,
1120, Vienna, Austria.
E-Mail:
Website: www.eutranslationalmedicine.org/pctm
Phone: +43 1 8923 562
Fax: +43 1 8923 562
Url: http://www.eutranslationalmedicine.org/pctm
| |
| Wednesday, September 09, 2015 |
 |
Cell & Gene Therapy Conference September 9-10, 2015 In Philadelphia, PA, USA ( 9:00 am )
Cell & Gene Therapy Conference September 9-10, 2015 in Philadelphia, PA, USAWe invite you to attend the 2nd Cell & Gene Therapy Conference, which will take place September 9-10, 2015 in Philadelphia, PA. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues and gain fresh perspective on the various research. Treatment of disease using cell and gene therapy is now a reality. With emerging technologies and new clinical trials being developed and launched at a growing rate, this meeting will discuss the evolving regulatory challenges and pre-clinical requirements, emerging technologies, the development and applications of cell and gene therapy, as well as business models and commercial milestones. Session Topics: I. Emerging Technologies II. Pre-clinical Research III. Clinical Development IV. Strategies for Commercialization V. Regulatory Challenges VI. Funding/Finance for Cell & Gene Therapy
Url: https://www.gtcbio.com/conferences/cell-gene-therapy-overview
| |
| Thursday, September 10, 2015 |
 |
Cell & Gene Therapy Conference September 9-10, 2015 In Philadelphia, PA, USA ( 9:00 am )
Cell & Gene Therapy Conference September 9-10, 2015 in Philadelphia, PA, USAWe invite you to attend the 2nd Cell & Gene Therapy Conference, which will take place September 9-10, 2015 in Philadelphia, PA. The conference will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues and gain fresh perspective on the various research. Treatment of disease using cell and gene therapy is now a reality. With emerging technologies and new clinical trials being developed and launched at a growing rate, this meeting will discuss the evolving regulatory challenges and pre-clinical requirements, emerging technologies, the development and applications of cell and gene therapy, as well as business models and commercial milestones. Session Topics: I. Emerging Technologies II. Pre-clinical Research III. Clinical Development IV. Strategies for Commercialization V. Regulatory Challenges VI. Funding/Finance for Cell & Gene Therapy
Url: https://www.gtcbio.com/conferences/cell-gene-therapy-overview
| |
| Monday, September 14, 2015 |
 |
FMC 2015 - Frontiers In Medicinal Chemistry Antwerp, Belgium - September 14-16, 2015 ( 8:00 am )
FMC 2015 - Frontiers in Medicinal Chemistry Antwerp, Belgium - September 14-16, 2015The Frontiers in Medicinal Chemistry symposium is co-organised on a biennial basis, as a collaboration between the ACS (American Chemical Society) and the EFMC (European Federation for Medicinal Chemistry).
Frontiers 2015 will take place in Antwerp, Belgium, from September 14-16, 2015. It will be jointly organised by EFMC, ACS and the local Dutch and Belgian organisers: the Medicinal and Bioorganic Chemistry Division of the Royal Flemish Chemical Society (KVCV, Belgium), the Société Royale de Chimie (SRC, Belgium), and the Section Medicinal Chemistry of the Royal Netherlands Chemical Society (KNCV, The Netherlands).
This biennial meeting is a key symposium in its field with traditionally around 300 participants, from industry and academia. It attracts a highly targeted audience composed of experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. The scientific programme for Frontiers 2015 will feature a plenary session, followed by sessions covering the latest advances in medicinal chemistry.
Url: http://www.frontiers2015.org
| |
| Tuesday, September 15, 2015 |
 |
FMC 2015 - Frontiers In Medicinal Chemistry Antwerp, Belgium - September 14-16, 2015 ( 8:00 am )
FMC 2015 - Frontiers in Medicinal Chemistry Antwerp, Belgium - September 14-16, 2015The Frontiers in Medicinal Chemistry symposium is co-organised on a biennial basis, as a collaboration between the ACS (American Chemical Society) and the EFMC (European Federation for Medicinal Chemistry).
Frontiers 2015 will take place in Antwerp, Belgium, from September 14-16, 2015. It will be jointly organised by EFMC, ACS and the local Dutch and Belgian organisers: the Medicinal and Bioorganic Chemistry Division of the Royal Flemish Chemical Society (KVCV, Belgium), the Société Royale de Chimie (SRC, Belgium), and the Section Medicinal Chemistry of the Royal Netherlands Chemical Society (KNCV, The Netherlands).
This biennial meeting is a key symposium in its field with traditionally around 300 participants, from industry and academia. It attracts a highly targeted audience composed of experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. The scientific programme for Frontiers 2015 will feature a plenary session, followed by sessions covering the latest advances in medicinal chemistry.
Url: http://www.frontiers2015.org
| |
| Wednesday, September 16, 2015 |
 |
FMC 2015 - Frontiers In Medicinal Chemistry Antwerp, Belgium - September 14-16, 2015 ( 8:00 am )
FMC 2015 - Frontiers in Medicinal Chemistry Antwerp, Belgium - September 14-16, 2015The Frontiers in Medicinal Chemistry symposium is co-organised on a biennial basis, as a collaboration between the ACS (American Chemical Society) and the EFMC (European Federation for Medicinal Chemistry).
Frontiers 2015 will take place in Antwerp, Belgium, from September 14-16, 2015. It will be jointly organised by EFMC, ACS and the local Dutch and Belgian organisers: the Medicinal and Bioorganic Chemistry Division of the Royal Flemish Chemical Society (KVCV, Belgium), the Société Royale de Chimie (SRC, Belgium), and the Section Medicinal Chemistry of the Royal Netherlands Chemical Society (KNCV, The Netherlands).
This biennial meeting is a key symposium in its field with traditionally around 300 participants, from industry and academia. It attracts a highly targeted audience composed of experts in drug discovery and development, in particular medicinal and synthetic chemists, together with scientists active in the fields of computer assisted drug design, biology, DMPK, pharmacology, early toxicology, as well as chemical and pharmaceutical development. The scientific programme for Frontiers 2015 will feature a plenary session, followed by sessions covering the latest advances in medicinal chemistry.
Url: http://www.frontiers2015.org
| |
 |
Cancer Vaccines 16th – 17th September 2015 Marriott Regents Park, London ( 9:00 am )
Cancer Vaccines 16th – 17th September 2015 Marriott Regents Park, LondonCancer Vaccines helps to boost the immune system's recognition
and resistance to cancer cells. Thus, increased knowledge of our immune
system has opened up new combination therapies in immuno-oncology, to
enhance immune response, as some the latest treatments incorporate
monoclonal antibodies and genetically engineered viral vectors to kill
tumours.
Some of the hottest topics will include:
• CAR T-Cell Therapy
• Oncolytic viral therapies
• Gene-therapy
• Adoptive T-Cell transfer
In addition, two- panel discussions on both days will bring some key
questions to light including the commercial vial ability of personalised
treatments. However, it has also become clear that cancer cells have different
ways of eluding the immune system, which makes creating effective
vaccines difficult.
Researchers are also studying the best way to give vaccines, looking
to see if they work better when used alone or with other types of cancer
treatments. Therefore key discussion points in our 2-day interactive
panel will include:
- Development of combination treatments - which ones are best?
- Driving the next generation tools in cancer immunotherapy
- How will technology and data systems need to change in order to allow personalised treatment to evolve?
+44 (0)20 7827 6000
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Cancer Vaccines
16th September to 17th September 2015, London, United Kingdom
Register by 29/05/2015 and Save
 Cancer
Vaccines helps to boost the immune system's recognition
and resistance to cancer cells. Thus, increased knowledge of our immune
system has opened up new combination therapies in immuno-oncology, to
enhance immune response, as some the latest treatments incorporate
monoclonal antibodies and genetically engineered viral vectors to kill
tumours.
Some of the hottest topics will include:
• CAR T-Cell Therapy
• Oncolytic viral therapies
• Gene-therapy
• Adoptive T-Cell transfer
In addition, two- panel discussions on both days will bring some key
questions to light including the commercial vial ability of personalised
treatments.
However, it has also become clear that cancer cells have
different ways of eluding the immune system, which makes creating
effective vaccines difficult.
Researchers are also studying the best way to give vaccines, looking
to see if they work better when used alone or with other types of cancer
treatments. Therefore key discussion points in our 2-day interactive
panel will include:
- Development of combination treatments - which ones are best?
- Driving the next generation tools in cancer immunotherapy
- How will technology and data systems need to change in order to allow personalised treatment to evolve?

Url: https://www.smi-online.co.uk/pharmaceuticals/uk/conference/cancer-vaccines

| |
| Thursday, September 17, 2015 |
 |
Cancer Vaccines 16th – 17th September 2015 Marriott Regents Park, London ( 9:00 am )
Cancer Vaccines 16th – 17th September 2015 Marriott Regents Park, LondonCancer Vaccines helps to boost the immune system's recognition
and resistance to cancer cells. Thus, increased knowledge of our immune
system has opened up new combination therapies in immuno-oncology, to
enhance immune response, as some the latest treatments incorporate
monoclonal antibodies and genetically engineered viral vectors to kill
tumours.
Some of the hottest topics will include:
• CAR T-Cell Therapy
• Oncolytic viral therapies
• Gene-therapy
• Adoptive T-Cell transfer
In addition, two- panel discussions on both days will bring some key
questions to light including the commercial vial ability of personalised
treatments. However, it has also become clear that cancer cells have different
ways of eluding the immune system, which makes creating effective
vaccines difficult.
Researchers are also studying the best way to give vaccines, looking
to see if they work better when used alone or with other types of cancer
treatments. Therefore key discussion points in our 2-day interactive
panel will include:
- Development of combination treatments - which ones are best?
- Driving the next generation tools in cancer immunotherapy
- How will technology and data systems need to change in order to allow personalised treatment to evolve?
+44 (0)20 7827 6000
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Cancer Vaccines
16th September to 17th September 2015, London, United Kingdom
Register by 29/05/2015 and Save
 Cancer
Vaccines helps to boost the immune system's recognition
and resistance to cancer cells. Thus, increased knowledge of our immune
system has opened up new combination therapies in immuno-oncology, to
enhance immune response, as some the latest treatments incorporate
monoclonal antibodies and genetically engineered viral vectors to kill
tumours.
Some of the hottest topics will include:
• CAR T-Cell Therapy
• Oncolytic viral therapies
• Gene-therapy
• Adoptive T-Cell transfer
In addition, two- panel discussions on both days will bring some key
questions to light including the commercial vial ability of personalised
treatments.
However, it has also become clear that cancer cells have
different ways of eluding the immune system, which makes creating
effective vaccines difficult.
Researchers are also studying the best way to give vaccines, looking
to see if they work better when used alone or with other types of cancer
treatments. Therefore key discussion points in our 2-day interactive
panel will include:
- Development of combination treatments - which ones are best?
- Driving the next generation tools in cancer immunotherapy
- How will technology and data systems need to change in order to allow personalised treatment to evolve?

Url: https://www.smi-online.co.uk/pharmaceuticals/uk/conference/cancer-vaccines

| |
|
|
| Friday, September 18, 2015 |
|
|
|
|
| Saturday, September 19, 2015 |
|
|
| Tuesday, September 22, 2015 |
|
|
|
|
| Wednesday, September 23, 2015 |
|
|
|
|
| Thursday, September 24, 2015 |
|
|
| Friday, September 25, 2015 |
|
|
| Sunday, September 27, 2015 |
 |
11th EFMC Short Course On Medicinal Chemistry Engineering Of Biopharmaceuticals ( 9:00 am )
11th EFMC Short Course on Medicinal ChemistryEngineering of BiopharmaceuticalsOegstgeest (near Leiden), The Netherlands - September 27-30, 2015This intensive course is intended for scientists with interests in the field of peptide and protein engineering covering topics around synthetic peptides, engineered proteins and therapeutic antibodies.
The number of participants will be limited to 35 to assure the possibility for in-depth discussions. The presentations and tutorials will be given by academic and industrial experts and will cover broad historical perspectives and in depth details of important engineering technologies. The presenters will also include interesting applications as well as future aspects in an informal approach aiming for high level of interaction of the participants.
Course outline
The development of future biopharmaceuticals will depend on research at the interfaces between several scientific disciplines including organic chemistry, physical chemistry, biophysics, protein chemistry and molecular biology. The interplay between these fields will have a key role for improving our molecular understanding of peptides and proteins and thus for developing future drug candidates. This course will focus on strategies on how to design and engineer biopharmaceuticals and will provide participants with insight to this important field of bioscience, which are applicable in academic and pharmaceutical contexts. The course will cover several fundamental aspects of peptide chemistry methodologies, selective modifications of proteins, ligation chemistries and regioselective coupling reactions. The biophysical characterization of peptide and proteins will be integrated in the lectures. The course will also cover various methods of semi-synthetic and synthetic modifications of proteins with focus on the application to drug discovery. Finally the course will give an insight to therapeutic antibodiesincluding screening, optimization an engineering aspects.
Thus, various issues of development of biopharmaceuticals as well as discussions of different strategies to improve peptide and protein properties to biopharmaceuticals will be the primary focus of the course.
Register before the deadline of June 22!
Interested participants are asked to pre-register for the course. A final registration confirmation will be sent after the pre-registration deadline of June 22. In case of an insufficient number of participants, EFMC reserves the right to cancel the course.
Comments of previous EFMC Short Course Participants
- “Very nice set-up. Limited number of participants. Excellent opportunity to speak to peers about medchem issues and others.”
- “The availability of the speakers during the sessions and exercises was a plus. The tutors were very experienced, motivated and motivating, and very good in communication."
- “Having the whole meeting 'under one roof' is appreciated. The castle is a very nice and comfortable location to organise an event such as the Short Course.”
- "The speakers of the Engineering of Biopharmaceuticals Course (Spring 2014) were of high quality and well prepared.”
Course Organiser Jesper LAU (Novo Nordisk, Denmark)
Local Organiser Henk TIMMERMAN (VU University Amsterdam, The Netherlands)
Registration fee €1.675 – including accommodation, breakfast, coffee breaks, lunches and dinners during the 3 days of the course.
More information on registration can be found on www.efmcshortcourses.org
Url: http://www.efmcshortcourses.org
| |
| Monday, September 28, 2015 |
 |
11th EFMC Short Course On Medicinal Chemistry Engineering Of Biopharmaceuticals ( 9:00 am )
11th EFMC Short Course on Medicinal ChemistryEngineering of BiopharmaceuticalsOegstgeest (near Leiden), The Netherlands - September 27-30, 2015This intensive course is intended for scientists with interests in the field of peptide and protein engineering covering topics around synthetic peptides, engineered proteins and therapeutic antibodies.
The number of participants will be limited to 35 to assure the possibility for in-depth discussions. The presentations and tutorials will be given by academic and industrial experts and will cover broad historical perspectives and in depth details of important engineering technologies. The presenters will also include interesting applications as well as future aspects in an informal approach aiming for high level of interaction of the participants.
Course outline
The development of future biopharmaceuticals will depend on research at the interfaces between several scientific disciplines including organic chemistry, physical chemistry, biophysics, protein chemistry and molecular biology. The interplay between these fields will have a key role for improving our molecular understanding of peptides and proteins and thus for developing future drug candidates. This course will focus on strategies on how to design and engineer biopharmaceuticals and will provide participants with insight to this important field of bioscience, which are applicable in academic and pharmaceutical contexts. The course will cover several fundamental aspects of peptide chemistry methodologies, selective modifications of proteins, ligation chemistries and regioselective coupling reactions. The biophysical characterization of peptide and proteins will be integrated in the lectures. The course will also cover various methods of semi-synthetic and synthetic modifications of proteins with focus on the application to drug discovery. Finally the course will give an insight to therapeutic antibodiesincluding screening, optimization an engineering aspects.
Thus, various issues of development of biopharmaceuticals as well as discussions of different strategies to improve peptide and protein properties to biopharmaceuticals will be the primary focus of the course.
Register before the deadline of June 22!
Interested participants are asked to pre-register for the course. A final registration confirmation will be sent after the pre-registration deadline of June 22. In case of an insufficient number of participants, EFMC reserves the right to cancel the course.
Comments of previous EFMC Short Course Participants
- “Very nice set-up. Limited number of participants. Excellent opportunity to speak to peers about medchem issues and others.”
- “The availability of the speakers during the sessions and exercises was a plus. The tutors were very experienced, motivated and motivating, and very good in communication."
- “Having the whole meeting 'under one roof' is appreciated. The castle is a very nice and comfortable location to organise an event such as the Short Course.”
- "The speakers of the Engineering of Biopharmaceuticals Course (Spring 2014) were of high quality and well prepared.”
Course Organiser Jesper LAU (Novo Nordisk, Denmark)
Local Organiser Henk TIMMERMAN (VU University Amsterdam, The Netherlands)
Registration fee €1.675 – including accommodation, breakfast, coffee breaks, lunches and dinners during the 3 days of the course.
More information on registration can be found on www.efmcshortcourses.org
Url: http://www.efmcshortcourses.org
| |
| Tuesday, September 29, 2015 |
 |
11th EFMC Short Course On Medicinal Chemistry Engineering Of Biopharmaceuticals ( 9:00 am )
11th EFMC Short Course on Medicinal ChemistryEngineering of BiopharmaceuticalsOegstgeest (near Leiden), The Netherlands - September 27-30, 2015This intensive course is intended for scientists with interests in the field of peptide and protein engineering covering topics around synthetic peptides, engineered proteins and therapeutic antibodies.
The number of participants will be limited to 35 to assure the possibility for in-depth discussions. The presentations and tutorials will be given by academic and industrial experts and will cover broad historical perspectives and in depth details of important engineering technologies. The presenters will also include interesting applications as well as future aspects in an informal approach aiming for high level of interaction of the participants.
Course outline
The development of future biopharmaceuticals will depend on research at the interfaces between several scientific disciplines including organic chemistry, physical chemistry, biophysics, protein chemistry and molecular biology. The interplay between these fields will have a key role for improving our molecular understanding of peptides and proteins and thus for developing future drug candidates. This course will focus on strategies on how to design and engineer biopharmaceuticals and will provide participants with insight to this important field of bioscience, which are applicable in academic and pharmaceutical contexts. The course will cover several fundamental aspects of peptide chemistry methodologies, selective modifications of proteins, ligation chemistries and regioselective coupling reactions. The biophysical characterization of peptide and proteins will be integrated in the lectures. The course will also cover various methods of semi-synthetic and synthetic modifications of proteins with focus on the application to drug discovery. Finally the course will give an insight to therapeutic antibodiesincluding screening, optimization an engineering aspects.
Thus, various issues of development of biopharmaceuticals as well as discussions of different strategies to improve peptide and protein properties to biopharmaceuticals will be the primary focus of the course.
Register before the deadline of June 22!
Interested participants are asked to pre-register for the course. A final registration confirmation will be sent after the pre-registration deadline of June 22. In case of an insufficient number of participants, EFMC reserves the right to cancel the course.
Comments of previous EFMC Short Course Participants
- “Very nice set-up. Limited number of participants. Excellent opportunity to speak to peers about medchem issues and others.”
- “The availability of the speakers during the sessions and exercises was a plus. The tutors were very experienced, motivated and motivating, and very good in communication."
- “Having the whole meeting 'under one roof' is appreciated. The castle is a very nice and comfortable location to organise an event such as the Short Course.”
- "The speakers of the Engineering of Biopharmaceuticals Course (Spring 2014) were of high quality and well prepared.”
Course Organiser Jesper LAU (Novo Nordisk, Denmark)
Local Organiser Henk TIMMERMAN (VU University Amsterdam, The Netherlands)
Registration fee €1.675 – including accommodation, breakfast, coffee breaks, lunches and dinners during the 3 days of the course.
More information on registration can be found on www.efmcshortcourses.org
Url: http://www.efmcshortcourses.org
| |
| Wednesday, September 30, 2015 |
 |
11th EFMC Short Course On Medicinal Chemistry Engineering Of Biopharmaceuticals ( 9:00 am )
11th EFMC Short Course on Medicinal ChemistryEngineering of BiopharmaceuticalsOegstgeest (near Leiden), The Netherlands - September 27-30, 2015This intensive course is intended for scientists with interests in the field of peptide and protein engineering covering topics around synthetic peptides, engineered proteins and therapeutic antibodies.
The number of participants will be limited to 35 to assure the possibility for in-depth discussions. The presentations and tutorials will be given by academic and industrial experts and will cover broad historical perspectives and in depth details of important engineering technologies. The presenters will also include interesting applications as well as future aspects in an informal approach aiming for high level of interaction of the participants.
Course outline
The development of future biopharmaceuticals will depend on research at the interfaces between several scientific disciplines including organic chemistry, physical chemistry, biophysics, protein chemistry and molecular biology. The interplay between these fields will have a key role for improving our molecular understanding of peptides and proteins and thus for developing future drug candidates. This course will focus on strategies on how to design and engineer biopharmaceuticals and will provide participants with insight to this important field of bioscience, which are applicable in academic and pharmaceutical contexts. The course will cover several fundamental aspects of peptide chemistry methodologies, selective modifications of proteins, ligation chemistries and regioselective coupling reactions. The biophysical characterization of peptide and proteins will be integrated in the lectures. The course will also cover various methods of semi-synthetic and synthetic modifications of proteins with focus on the application to drug discovery. Finally the course will give an insight to therapeutic antibodiesincluding screening, optimization an engineering aspects.
Thus, various issues of development of biopharmaceuticals as well as discussions of different strategies to improve peptide and protein properties to biopharmaceuticals will be the primary focus of the course.
Register before the deadline of June 22!
Interested participants are asked to pre-register for the course. A final registration confirmation will be sent after the pre-registration deadline of June 22. In case of an insufficient number of participants, EFMC reserves the right to cancel the course.
Comments of previous EFMC Short Course Participants
- “Very nice set-up. Limited number of participants. Excellent opportunity to speak to peers about medchem issues and others.”
- “The availability of the speakers during the sessions and exercises was a plus. The tutors were very experienced, motivated and motivating, and very good in communication."
- “Having the whole meeting 'under one roof' is appreciated. The castle is a very nice and comfortable location to organise an event such as the Short Course.”
- "The speakers of the Engineering of Biopharmaceuticals Course (Spring 2014) were of high quality and well prepared.”
Course Organiser Jesper LAU (Novo Nordisk, Denmark)
Local Organiser Henk TIMMERMAN (VU University Amsterdam, The Netherlands)
Registration fee €1.675 – including accommodation, breakfast, coffee breaks, lunches and dinners during the 3 days of the course.
More information on registration can be found on www.efmcshortcourses.org
Url: http://www.efmcshortcourses.org
| |
 |
Biosimilars And Biobetters 30th September – 1st October 2015 Holiday Inn Kensington Forum, London ( 9:00 am )
Biosimilars and Biobetters 30th September – 1st October 2015 Holiday Inn Kensington Forum, LondonThe development of the Biosimilars market is growing exponentially with the industry forecast to be worth $25 billion by 2020. With the regulatory landscape evolving rapidly, it is important to understand the developments in the biosimilar guideline framework and the cohesion in legislation between Europe and the US.
With Europe leading the way in the field of Biosimilar development, it is important to get to grips with all areas in the product lifecycle from early stage developments, protein characterisation and analytical comparability to patent litigation, market access, pricing and reimbursement through to emerging markets and global developments. Every angle should be considered and taken account for through the development process and with the EU the most advanced market for biosimilars, accounting for 80% of global spending on these molecules, the learning curve for biosimilars is essentially still building and there are hurdles to overcome.
Unlocking the potential of biosimilars will require a focused strategy along the whole value chain, from optimizing the clinical development program through developing the most suitable strategy for commercialisation.
Url: https://www.smi-online.co.uk/pharmaceuticals/uk/conference/biosimilars-and-biobetters
| |